Clinical Trial

Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
In Bangladesh Melatonin is currently used for insomnia. Its potential therapeutic benefits beyond sleep regulation. This study aimss to evaluate the effects of melatonin supplementation on oxidative stress markers, neuroinflammation and clinical outcomes in patients with Parkinson's disease. The main question it aims to answer: In patients with Parkinson's disease receiving levodopa, does melatonin supplementation, compared to levodopa treatment alone, improve the symptoms of PD over a 12 week of period. Participants will: Take Melatonin 10mg or placebo everyday for 3 months at night 30minutes before bedtime. Visit the clinic once every 6 weeks for checkups and tests keep a diary of their symptoms,UPDRS score. At the end of 12 weeks will reaper hs-CRP, MDA and GSH.
Trial Details
NCT Number NCT07375693
Lead Sponsor Bangladesh Medical University
Conditions Parkinson Disease
Enrollment 70 participants
Start Date 2026-02-17
Primary Completion 2026-08-23 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-29